CRC Research Update — October 30, 2026
Today's colorectal cancer research highlights
Archive
A collection of 943 issues
Latest
New predictive model identifies mismatch repair deficiency in resource-limited settings
Skip to content
The CRC Digest
New predictive model identifies mismatch repair deficiency in resource-limited settings
Cross-sectional analysis of 185 Sri Lankan patients found 12.4% were mismatch repair deficient; multivariable analysis identified age under 60, right-sided tumors, family history, and specific histologic features as significant predictors. (BMC Cancer)
This
Obesity reshapes gut microbiota and drives early-onset CRC through dysbiosis and inflammation
Skip to content
The CRC Digest
Obesity reshapes gut microbiota and drives early-onset CRC through dysbiosis and inflammation
Narrative review explores how diet-induced adiposity depletes protective bacteria, enriches genotoxic pathobionts, and promotes systemic inflammation that creates a fertile niche for early-onset carcinogenesis. (In Vivo)
This content is informational only and
Dual-gene stool DNA test achieves 82.9% sensitivity for colorectal cancer detection
Skip to content
The CRC Digest
▪ SCREENING
Dual-gene stool DNA test achieves 82.9% sensitivity for colorectal cancer detection
Cross-sectional study of 274 participants found combined SDC2 and ADHFE1 methylation analysis in stool samples detected colorectal cancer with 82.9% sensitivity and an AUC of 0.865, though discrimination of
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Skip to content
The CRC Digest
◇ RESEARCH
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Laboratory study found PIK3C3 knockdown increased 5-fluorouracil resistance in KRAS-wild-type cells but enhanced sensitivity in KRAS-mutant cells, potentially through thymidylate synthase regulation. (Cancer Medicine)
This content is informational only and does
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Meta-analysis of 18 randomized trials (11,931 participants) found pooled median overall survival of 22.3 months for BRAF-directed regimens versus 10.1 months for EGFR-directed therapy in first-line treatment. (Journal of Gastrointestinal
Single-cell atlas reveals early-onset colorectal cancer has more stroma, less tumor epithelium
Skip to content
The CRC Digest
◇ RESEARCH
Single-cell atlas reveals early-onset colorectal cancer has more stroma, less tumor epithelium
Analysis of 189 tumors spanning eight decades found that microsatellite-stable tumors from younger patients had increased stromal and decreased epithelial proportions, with epithelial cells showing higher expression of long noncoding RNAs
CRC Research Update — October 29, 2026
Today's colorectal cancer research highlights
Pharmacokinetic method developed for pan-RAS inhibitor
Skip to content
The CRC Digest
▸ TREATMENT
Pharmacokinetic method developed for pan-RAS inhibitor
Researchers validated a mass spectrometry assay to measure daraxonrasib, an oral pan-RAS inhibitor in clinical evaluation for colorectal cancer, in canine plasma and whole blood, supporting pharmacokinetic characterization of the investigational drug. (Biomed Chromatogr)
This content is
Review outlines strategies for identifying Lynch syndrome
Skip to content
The CRC Digest
◇ RESEARCH
Review outlines strategies for identifying Lynch syndrome
A review in Familial Cancer summarizes established and emerging approaches to Lynch syndrome detection in patients with colorectal neoplasia, noting that tumor-based mismatch repair testing remains cost-efficient but limited by incomplete implementation, while direct germline testing
Early-onset CRC shows distinct immune landscape
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Early-onset CRC shows distinct immune landscape
A review in Cancer Immunology Research synthesizes evidence on the tumor-immune microenvironment of colorectal cancer diagnosed before age 50, highlighting differences in immune composition, functional states, and spatial organization that may inform prevention strategies and
Liquid biopsy detects residual disease after oligometastasis surgery
Skip to content
The CRC Digest
▪ SCREENING
Liquid biopsy detects residual disease after oligometastasis surgery
A prospective multicenter study of 118 patients with resectable colorectal oligometastases found that combining pretreatment circulating tumor DNA genomic profiling with post-operative molecular residual disease (MRD) detection identified patients at highest risk of recurrence, with
CRC Research Update — October 28, 2026
Today's colorectal cancer research highlights
WRN helicase emerges as therapeutic target in MSI-H colorectal cancer
Skip to content
The CRC Digest
WRN helicase emerges as therapeutic target in MSI-H colorectal cancer
MSI-H and mismatch repair-deficient cancers show dependence on Werner syndrome RecQ helicase (WRN), a synthetic-lethal vulnerability linked to expanded TA-dinucleotide repeats and replication-associated genome instability, though dependency is not universal among all MSI-H tumors.
Elevated troponin before chemotherapy predicts cardiovascular events during treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Elevated troponin before chemotherapy predicts cardiovascular events during treatment
Among 180 colorectal cancer patients starting 5-fluorouracil-based chemotherapy, baseline high-sensitivity troponin T above 14 ng/L was independently associated with major cardiovascular events, with more than half occurring within the first two
Inflammation-nutrition score predicts response to neoadjuvant therapy in rectal cancer
Skip to content
The CRC Digest
▸ TREATMENT
Inflammation-nutrition score predicts response to neoadjuvant therapy in rectal cancer
In 312 patients with locally advanced rectal cancer, a low pretreatment inflammation-nutrition prognostic score (INPS) was independently associated with higher response rates (61% vs. 29%) and pathological complete response (39% vs. 12%), outperforming
Multiple intratumoral bacteria show stronger association with colorectal cancer than single species
Skip to content
The CRC Digest
◇ RESEARCH
Multiple intratumoral bacteria show stronger association with colorectal cancer than single species
A Vietnamese cohort study found that co-detection of three bacterial species (F. nucleatum, A. muciniphila, and eae+ E. coli) was associated with a 21-fold increased odds of colorectal cancer compared to
Blood-based Shield test detects 83% of colorectal cancers but only 13% of advanced precancerous lesions
Skip to content
The CRC Digest
▪ SCREENING
Blood-based Shield test detects 83% of colorectal cancers but only 13% of advanced precancerous lesions
In the large-scale ECLIPSE study of average-risk individuals, the Shield cell-free DNA assay showed 83.1% sensitivity for colorectal cancer but only 13.2% sensitivity for advanced precancerous
CRC Research Update — October 27, 2026
Today's colorectal cancer research highlights
Rural residents more likely to pay full cost of colonoscopy
Skip to content
The CRC Digest
Rural residents more likely to pay full cost of colonoscopy
A national survey found 4.12% of rural residents reported paying all colonoscopy costs versus 3.01% of urban residents, with uninsured status and Hispanic ethnicity also associated with higher out-of-pocket spending. (Journal of